SOPHiA GENETICS

SOPHiA GENETICS is a health technology company founded in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz at EPFL in Switzerland, with current operations based in Rolle, Switzerland and Boston, United States. It was created to make genomic data analysis for precision medicine accessible to hospitals and laboratories without requiring in-house bioinformatics teams.

The company sells the SOPHiA DDM cloud software platform, which includes modules for genomics, radiomics, and multimodal data analysis in oncology and rare disorders, along with add-ons such as Alamut Visual Plus for variant annotation and OncoPortal for treatment decision support. It reports having analysed more than 2.6 million genomic profiles across over 1,000 healthcare institutions in more than 75 countries, and listed on Nasdaq in 2021.

1. SOPHiA DDM for Genomics: analysis of sequencing data for oncology and rare disorders.

2. SOPHiA DDM for Radiomics: analysis of medical imaging combined with genomic data.

3. Alamut Visual Plus: variant annotation and interpretation tool.

4. OncoPortal: module supporting cancer treatment decisions.

5. More than 2.6 million genomic profiles analysed across 1,000+ healthcare institutions.

6. Listed on Nasdaq under ticker SOPH since 2021.